Tumor-selective combination therapy

US10576096B2 · kind B2 · utility

Assignees

• The Board of Regents of the University of Texas System · US
• The Board of Trustees of the University of Illinois · US

Inventors

• Paul J. Hergenrother · Champaign, US
• David Boothman · Dallas, US
• Joseph S. Bair · Albany, US
• Lifen Cao · Dallas, US
• Jinming Gao · Dallas, US
• Xiumei HUANG · Dallas, US
• Xiuquan Luo · Plano, US
• Xinpeng MA · Cambridge, US
• Zachary R. Moore · Dallas, US
• Elizabeth I. Parkinson · Champaign, US

Key dates

• Filing date: Dec 6, 2017
• Grant date: Mar 3, 2020
• Expiry date: Dec 6, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.